A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)

被引：0
|
作者：
Kittai, Adam
Skarbnik, Alan
Miranda, Miguel
Yong, Alan S. M.
Roos, Jack
Hettle, Robert
Palazuelos-Munoz, Sarah
Shetty, Vikram
Ghia, Paolo
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[2] Novant Hlth Canc Inst, Charlotte, NC USA
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Wilmington, DE USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] IRCCS Osped San Raffaele, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients
    Ahmed, Tamer
    Hayslip, John
    Leggas, Markos
    CANCER RESEARCH, 2012, 72
  • [33] Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
    Loretta J. Nastoupil
    Ashley Bonner
    Pearl Wang
    Lamees Almuallem
    Jigar Desai
    Thalia Farazi
    Jinender Kumar
    Saurabh Dahiya
    Experimental Hematology & Oncology, 14 (1)
  • [34] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Jurczak, Wojciech
    Elmusharaf, Nagah
    Fox, Christopher P.
    Townsend, William
    Paulovich, Amanda G.
    Sharma, Shringi
    Parr, Graeme
    Munugalavadla, Veerendra
    Krantz, Fanny
    Yang, Helen
    Dean, Emma
    Manwani, Richa
    Hillmen, Peter
    CANCER RESEARCH, 2022, 82 (12)
  • [35] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S524 - S524
  • [36] Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Hamadani, Mehdi
    Chen, Lei
    Song, Yan
    Xu, Michael K.
    Liao, Laura
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E738 - E744
  • [37] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VERSUS SELINEXOR-DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Otero, Rodriguez P.
    Martin, T.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    VALUE IN HEALTH, 2023, 26 (12) : S31 - S31
  • [38] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Jacob, Abraham
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 141 - 142
  • [39] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
  • [40] Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
    Signorovitch, James E.
    Wu, Eric Q.
    Betts, Keith A.
    Parikh, Kejal
    Kantor, Evan
    Guo, Amy
    Bollu, Vamsi K.
    Williams, Denise
    Wei, L. J.
    DeAngelo, Daniel J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (06) : 1263 - 1271
12345